Rafat Abonour, MD, of the Indiana University School of Medicine, discusses what nurses should know about the recently expanded indication for idecabtagene vicleucel and the KarMMa-3 trial results that it was based on.
“The progression-free survival endpoint was met… The responses were incredible,” Dr. Abonour said of the KarMMa-3 trial results.